Photo from W. Michael Korn/LinkedIn
Oct 2, 2023, 18:25
W. Michael Korn: The FDA just granted marketing authorization for the Invitae Common Hereditary Cancers Panel.
W. Michael Korn, Chief Medical Officer for Oncology at Invitae, shared on LinkedIn:
“The FDA just granted marketing authorization for the Invitae Common Hereditary Cancers Panel. This is a first-in-class authorization for a DNA test capable of assessing predisposition to a multitude of cancer types – a fantastic testament to Invitae’s high-quality testing capabilities and the incredible people at Invitae who made this happen. The FDA decision is a major win for patients, providing access to high-quality testing with broad clinical utility.”
For details click here.
Source: W. Michael Korn/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 22, 2024, 05:31
Dec 22, 2024, 05:05